Meeting Information - The shareholder meeting is scheduled for October 20, 2025, starting at 14:00, with online voting available from 9:15 to 15:00 on the same day [1] - The meeting will be held at the company's administrative building in Xinchang, Zhejiang Province [1] - The meeting will combine on-site and online voting methods [1] Shareholder Participation - A total of 205 participants, including shareholders and their proxies, attended the meeting, representing 336,073,660 voting shares, which is 41.2990% of the total voting shares [4] - Nine shareholders attended the meeting in person, representing 320,161,302 voting shares, or 39.3436% of the total [5] - 196 shareholders participated through online voting, representing 15,912,358 voting shares, or 1.9554% of the total [6] - Among the participants, 201 were small and medium investors, representing 18,736,326 voting shares, or 2.3024% of the total [7] Proposals Reviewed - The meeting approved the proposal regarding the "Fourth Employee Stock Ownership Plan (Draft)" with 333,752,180 votes in favor, accounting for 99.3092% of the valid votes [9] - The proposal for the "Fourth Employee Stock Ownership Plan Management Measures" was also approved with 333,752,480 votes in favor, representing 99.3093% of the valid votes [10] - The proposal to authorize the board to handle matters related to the fourth employee stock ownership plan was approved with 333,749,880 votes in favor, which is 99.3085% of the valid votes [11] Legal Compliance - The meeting was attended by a lawyer from Shanghai Jintiancheng Law Firm, who confirmed that the meeting's procedures and resolutions complied with relevant laws and regulations [12]

证券代码：002020 证券简称：京新药业 公告编号：2025057 浙江京新药业股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 重要提示： 1、本次股东会无否决提案的情况； 2、本次股东会以现场投票和网络投票相结合的方式召开。 一、会议召开情况 1、本次股东会的召开时间 现场会议时间：2025 年 10 月 20 日 14:00 起。 6、本次会议的召集、召开与表决程序符合有关法律、法规、规章和公司章 1 程的规定。 二、会议出席情况 网络投票：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 10 月 20 日 9:15—9:25,9:30—11:30 和 13:00—15:00；通过深圳证券交易 所互联网投票系统进行网络投票的具体时间为 2025 年 10 月 20 日 9:15 至 15:00 的任意时间。 2、现场会议地点：浙江省新昌县羽林街道新昌大道东路 800 号本公司行政 楼一楼会议室。 3、会议召开方式：本次会议采取现场投票与网络投票相结合的方式。本次 股东会通过深圳证券交易所交 ...

上海市锦天城律师事务所 关于浙江京新药业股份有限公司 2025 年第二次临时股东会的 上海市锦天城律师事务所 法律意见书 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于浙江京新药业股份有限公司 2025 年第二次临时股东会的 法律意见书 致：浙江京新药业股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受浙江京新药业股份有限公 司（以下简称"公司"或"京新药业"）委托，就公司召开 2025 年第二次临时股东 会（以下简称"本次股东会"）的有关事宜，根据《中华人民共和国公司法》（以 下简称《公司法》）、《上市公司股东会规则》等法律、法规、规章和其他规范性 文件以及《浙江京新药业股份有限公司章程》（以下简称《公司章程》）的有关规 定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚 ...

Group 1 - The company, Jingxin Pharmaceutical (002020), stated on October 17 that it will disclose the number of shareholders at the end of the reporting period in its regular reports [1] - For non-regular reports, shareholders can provide proof of shareholding to the company's secretary office, which will verify and provide the information [1]

Core Viewpoint - The company emphasizes its commitment to improving operational performance while also focusing on market value management to enhance shareholder returns [1] Group 1 - The company is dedicated to achieving better operational results [1] - The company aims to effectively manage its market value [1] - The company seeks to provide returns to all shareholders [1]

Market Overview - On October 15, global markets experienced a significant recovery, with A-shares showing strong performance as the Shanghai Composite Index rose above 3900 points, closing up 1.22%, the Shenzhen Component up 1.73%, and the ChiNext Index up 2.36% [5][6] - A total of 4333 stocks rose, with 82 hitting the daily limit up, while 950 stocks declined [6][7] Sector Performance - The robotics sector saw substantial gains, with stocks like Sanhua Intelligent Control and Wuzhou New Spring hitting the daily limit up [7] - The innovative drug sector also surged, with stocks such as Angli Kang and Lianhuan Pharmaceutical reaching the daily limit up [8][9] - The automotive sector experienced a significant rise, with Zhongtong Bus and Haima Automobile hitting the daily limit up [10] Key Events Influencing the Market - Federal Reserve Chairman Jerome Powell hinted at potential interest rate cuts due to weak employment data, reinforcing expectations for further rate reductions [17] - A rumor regarding a substantial order from Tesla for robotics components valued at $685 million for Sanhua Intelligent Control contributed to the stock's surge [19] - New Kylin's subsidiary Qi Yun Fang launched two domestically developed EDA design software products, filling a gap in high-end electronic design software technology [20] - ASML reported better-than-expected orders driven by AI demand, with third-quarter orders totaling €5.4 billion ($6.3 billion), exceeding analyst expectations [22]

上海锦天城（杭州）律师事务所 关于浙江京新药业股份有限公司 第四期员工持股计划的 法律意见书 地址：杭州市上城区富春路 308 号华成国际发展大厦 11/12 层 电话：（86571）8983-8088 传真：（86571）8983-8099 邮编：310020 上海锦天城（杭州）律师事务所 法律意见书 上海锦天城（杭州）律师事务所 关于浙江京新药业股份有限公司 第四期员工持股计划的 法律意见书 致：浙江京新药业股份有限公司 上海锦天城（杭州）律师事务所（以下简称"本所"）接受浙江京新药业股 份有限公司（以下简称"京新药业"或"公司"）的委托，担任公司第四期员工 持股计划（以下简称"本次员工持股计划"）的法律顾问，根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简 称"《证券法》"）、《关于上市公司实施员工持股计划试点的指导意见》（以 下简称"《指导意见》"）、《深圳证券交易所上市公司自律监管指引第 1 号— —主板上市公司规范运作》（以下简称"《自律监管指引》"）、《上市公司股 权激励管理办法》（以下简称"《管理办法》"）等有关法律法规的规定，按照 律师行业公认的业务 ...

Core Viewpoint - Jingxin Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 51.26% but a recent decline in the last five and twenty trading days [1][2]. Financial Performance - For the first half of 2025, Jingxin Pharmaceutical reported revenue of 2.017 billion yuan, a year-on-year decrease of 6.20%, and a net profit attributable to shareholders of 388 million yuan, down 3.54% [2]. - The company has distributed a total of 2.11 billion yuan in dividends since its A-share listing, with 801 million yuan distributed over the past three years [3]. Stock Market Activity - As of October 14, the stock price was 18.86 yuan per share, with a market capitalization of 16.239 billion yuan. The trading volume was 111 million yuan, with a turnover rate of 0.80% [1]. - The stock has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) once this year, with a net buy of 111 million yuan on July 4 [1]. Shareholder Information - As of June 30, 2025, the number of shareholders was 25,700, a slight decrease of 0.11%, with an average of 28,196 circulating shares per shareholder, an increase of 0.11% [2]. - The fifth-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 9.6492 million shares, a decrease of 15.3917 million shares from the previous period [3].

Core Viewpoint - Jingxin Pharmaceutical (002020) is committed to improving its operational management to achieve better performance and return value to all shareholders [1] Group 1 - The company is actively engaging with investors through platforms to address their inquiries [1] - The management emphasizes the importance of operational efficiency in driving future growth [1]

Core Viewpoint - Jingxin Pharmaceutical's stock price has experienced fluctuations, with a year-to-date increase of 54.30% but a recent decline in the last five and twenty trading days [1][2]. Financial Performance - For the first half of 2025, Jingxin Pharmaceutical reported revenue of 2.017 billion yuan, a year-on-year decrease of 6.20%, and a net profit attributable to shareholders of 388 million yuan, down 3.54% year-on-year [2]. - The company has cumulatively distributed 2.11 billion yuan in dividends since its A-share listing, with 801 million yuan distributed over the past three years [3]. Stock Market Activity - As of October 13, the stock price was 19.24 yuan per share, with a market capitalization of 16.566 billion yuan. The trading volume was 156 million yuan, with a turnover rate of 1.11% [1]. - The stock has appeared on the "Dragon and Tiger List" once this year, with a net buy of 111 million yuan on July 4 [1]. Shareholder Information - As of June 30, 2025, the number of shareholders was 25,700, a decrease of 0.11% from the previous period, with an average of 28,196 circulating shares per shareholder, an increase of 0.11% [2]. - Hong Kong Central Clearing Limited is the fifth-largest circulating shareholder, holding 9.6492 million shares, a decrease of 15.3917 million shares from the previous period [3].